search
Back to results

Study on Mastocytosis for Rupatadine Treatment (SMART)

Primary Purpose

Mastocytosis

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Rupatadin
Sponsored by
Marcus Maurer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mastocytosis focused on measuring Assessment of wheal and flare development, Assessment of life quality

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign
  2. Age between 18 and 65 years.
  3. Female patients must be using a highly effective method of birth control (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, vasectomised partner), or they must be postmenopausal, surgically sterilised, or hysterectomised.
  4. Voluntarily signed written informed consent.

Exclusion Criteria:

  1. The presence of permanent severe diseases, especially those affecting the immune system, except for mastocytosis
  2. History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
  3. History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper-/hypokalemia, bradycardia < 50bpm, QTc interval > 440ms
  4. Evidence of severe renal dysfunction (creatinine > 1,5 x upper reference value)
  5. Evidence of significant hepatic disease (liver enzymes > 2 x upper reference value)
  6. History of adverse reactions to RUP, or other ingredients of the IMP
  7. Presence of active cancer which requires chemotherapy or radiation therapy
  8. Aggressive systemic mastocytosis
  9. History or presence of alcohol abuse or drug addiction
  10. Participation in any clinical trial within 4 weeks prior to enrolment
  11. Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG
  12. Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study
  13. Intake of oral corticosteroids within 14 days prior to the beginning of the study
  14. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study
  15. Pregnancy or breast-feeding

Sites / Locations

  • University Charité

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Sugar Pill

Rupafin

Arm Description

All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.

All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.

Outcomes

Primary Outcome Measures

Pruritus
Reduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.

Secondary Outcome Measures

Questionaire
Improvement of additional disease related symptoms and subjective affliction as measured by physician and patient global assessments, DLQI, Itchy-QoL and QoL(i)MaP*. *not validated questionnaire for mastocytosis symptoms

Full Information

First Posted
November 23, 2011
Last Updated
November 2, 2016
Sponsor
Marcus Maurer
search

1. Study Identification

Unique Protocol Identification Number
NCT01481909
Brief Title
Study on Mastocytosis for Rupatadine Treatment
Acronym
SMART
Official Title
Study on Mastocytosis for Rupatadine Treatment An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
November 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Marcus Maurer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study title: An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms. Study code: SMART-2010-1 Principal Investigator, Co-Investigator, sponsor, and study centre (acc. to § 40 Abs. 4 AMG) Dr. med. F. Siebenhaar, Prof. Dr. Med. M. Maurer, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Biometry and biostatistical analyses Division of Biostatistics and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Monitoring Coordination Centre for Clinical Studies (KKS), Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Clinical phase Phase II Primary objective: Reduction of wheal and flare type skin reaction after standardised provocation testing assessed by volumetric and thermographic measurements. Secondary objectives: Improvement of additional related symptoms (e.g. pruritus) and subjective affliction as assessed by symptom score, DLQI, Itchy-QoL and VAS. Study design: An exploratory, randomised, double-blind, placebo controlled crossover study Type and number of patients: Male and female patients (n = 30) with cutaneous mastocytosis and indolent systemic mastocytosis with skin involvement Main criteria for inclusion: Mastocytosis patients aged 18-65 years, signed written consent, no systemic corticosteroid or other immunosuppressive therapy, no permanent severe diseases Test product, dose and mode of administration 20 mg Rupatadine or placebo before provocation testing, oral administration (tablets) Duration of treatment: 28 days (testing will be done at the day of last treatment) Assessment of efficacy: Assessment of wheal and flare development by planimetric analyses of digital photographic, volumetric, and thermographic imaging (time lapse) before and after treatment with study medication, Additional assessment of symptoms, Assessment of life quality Main criteria of evaluation: Efficacy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mastocytosis
Keywords
Assessment of wheal and flare development, Assessment of life quality

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sugar Pill
Arm Type
Placebo Comparator
Arm Description
All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
Arm Title
Rupafin
Arm Type
Active Comparator
Arm Description
All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
Intervention Type
Drug
Intervention Name(s)
Rupatadin
Other Intervention Name(s)
Each tablet contains 10 mg RUP
Intervention Description
20 mg, 28 days over 60 days
Primary Outcome Measure Information:
Title
Pruritus
Description
Reduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Questionaire
Description
Improvement of additional disease related symptoms and subjective affliction as measured by physician and patient global assessments, DLQI, Itchy-QoL and QoL(i)MaP*. *not validated questionnaire for mastocytosis symptoms
Time Frame
10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign Age between 18 and 65 years. Female patients must be using a highly effective method of birth control (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, vasectomised partner), or they must be postmenopausal, surgically sterilised, or hysterectomised. Voluntarily signed written informed consent. Exclusion Criteria: The presence of permanent severe diseases, especially those affecting the immune system, except for mastocytosis History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper-/hypokalemia, bradycardia < 50bpm, QTc interval > 440ms Evidence of severe renal dysfunction (creatinine > 1,5 x upper reference value) Evidence of significant hepatic disease (liver enzymes > 2 x upper reference value) History of adverse reactions to RUP, or other ingredients of the IMP Presence of active cancer which requires chemotherapy or radiation therapy Aggressive systemic mastocytosis History or presence of alcohol abuse or drug addiction Participation in any clinical trial within 4 weeks prior to enrolment Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study Intake of oral corticosteroids within 14 days prior to the beginning of the study Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study Pregnancy or breast-feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcus Maurer, MD
Organizational Affiliation
University Berlin Charitè
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Charité
City
Berlin
ZIP/Postal Code
10117
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Study on Mastocytosis for Rupatadine Treatment

We'll reach out to this number within 24 hrs